Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1. 2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Narcolepsy is a rare chronic disorder